How changing your cancer pill's appearance affects your treatment
Part of Cancer clinical trials.
This study looks at how switching from a brand-name cancer pill to a generic version (or between two generics) affects your daily routine, ability to stay on treatment, and overall well-being. If you've been on one of these specific pills for at least 6 months and recently made a switch, the researchers want to learn from your experience.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are taking one of these oral cancer drugs: capecitabine, imatinib, everolimus, abiraterone, or lenalidomide.
- You have been on your current drug for at least 6 months.
- You recently switched from a brand drug to a generic, or from one generic to another.
- You are not picking up medicine for someone else, and you don't live in a nursing home or facility.
- You have not been in the hospital during the last 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a set of practical support steps to help people with advanced cancer take their oral (by mouth) treatment medicines correctly. It may help improve adherence and reduce missed doses or appointments.
This study tests a program to help people recently diagnosed with cancer stay on track with their regular medicines for other health conditions, like blood pressure or diabetes. It aims to make managing both cancer and chronic conditions easier.
This British Columbia study looks at how well different cancer treatments work in real life when doctors aren't sure which option is best. You and your doctor would choose a treatment, and researchers will track your results to help others.
This trial tests whether combining regular medication safety checks with electronic tracking of side effects can improve quality of life and help reduce economic burden for people taking cancer pills. It’s for people starting oral cancer therapy and using connected technology to report symptoms.
This trial studies whether a “DROP” support program helps ambulatory people with cancer manage drug-related problems when they start or change oral (by mouth) anticancer treatment. It may help reduce medication mistakes and complications by improving how you handle your regimen at home.
This study looks at whether adding extra support from a geriatric team and a pharmacist can help older patients (70+) take their oral cancer pills safely and effectively. You may be able to join if you are starting one of the listed oral therapies for your cancer.
Hear when a new Adherence, Patient trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.